Medivation Inc news

   Watch this stock
Showing stories 1 - 10 of about 14   

Articles published

MDVN 113.56
price chart
Medivation Emerges With New Prostate Cancer Drug
San Francisco-based Medivation doesn't quite have the brand name recognition of its rivals in the world of prostate cancer drug development, but that could be starting to change, as soon as this weekend.
Study: J&J's Zytiga Can Eliminate Some Prostate Tumors
Dr. Taplin and other researchers have started another study looking at Medivation Inc. MDVN -1.97 % 's experimental drug enzalutamide for use as a treatment before surgery.
J&J's Zytiga Helps Eliminate Early-Stage Prostate Cancer  Bloomberg
New Therapies for Prostate Cancer: The Practicalities
Unlike other cancers, the treatment options for prostate cancer have remained fairly consistent over the last decade. Research has been stymied by the bland molecular sub-characterization of prostate cancer in contrast to other cancers.
Optimal Sequencing for New Prostate Cancer Drugs: Interview with E. David ...  Renal and Urology News
Dendreon Meets Expectations with $82M in 1st Quarter Provenge Sales
Seattle-based Dendreon said back in February that it expected “moderate” first quarter sales growth with its prostate cancer drug, and now it's reporting it delivered on that projection, generating just enough sales to meet Wall Street expectations ...
Why I Gave Megrahi Three Months to Live
These include drugs such as abiraterone, cabazitaxel, alpharadin and medivation, which Megrahi probably received and are still not widely available in the U.K.
Dendreon's Provenge Works Best for Patients With Low PSA, Scientists Say
Since then, the company has faced a series of new competitive threats, particularly from Johnson & Johnson's abiraterone (Zytiga) and Medivation's enzalutamide. Those drugs are starting out by aiming to treat the sickest of prostate cancer patients ...
Dendreon: Timing Of News Story Release Is Interesting  Seeking Alpha
National Plan Long on Vision of Conquering Alzheimer Disease, Sketchy on ...
In January, Pfizer and Medivation ended a co-development and marketing collaboration on Dimebon (latrepirdine) after a Phase III trial did not meet either of its co-primary endpoints of improving cognition or self-care and daily function.
What You Must Know Before Investing in Prostate Cancer Stocks
At this point, the patients are classified as having Castrate Resistant Prostate Cancer (CRPC). CRPC is the target disease for Dendreon, Johnson & Johnson, Medivation, Exelixis, and several others so this is where all the action is. The urologist ...
Who's on Biotech's Endangered Species List? Mid-Sized Drugmakers
[Updated: 9:20 pm PT] Only a few companies have ever been successful enough to call themselves Big Biotechs. If boards and shareholders lack vision and guts, we'll look back in a few years and wonder why the Big Biotechs went extinct.
BMS may have another Avastin in its oncology pipeline, analyst says
That would have implications for biotech firm Medivation, as well, which is testing its own investigational agent, MDV3100, in patients with prostate cancer prior to chemo.